Researchers hunt for muscle clues in rare dystrophy
NCT ID NCT01851447
First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 10 times
Summary
This pilot study looks at biomarkers in the blood of people with fragile sarcolemmal muscular dystrophy, a condition that makes muscle membranes weak. Researchers will collect blood samples at rest and after exercise during four 5-day hospital stays. The goal is to better understand how the disease affects muscles, which could guide future treatments. No treatment is given in this study.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GENETIC DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Stress-Busting program help VHL patients cope better?
- Gene therapy readiness check: new study maps virus immunity in muscle disease patients
- Testosterone levels linked to brain health in new genetic analysis
- 110,000 patients join massive DNA study to unlock disease secrets
- Scientists hunt for genes behind puberty problems
- NIH study aims to sharpen research skills by evaluating kids with genetic disorders